Terms: = Breast cancer AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H AND Prognosis
379 results:
1. Chemotherapy-elicited extracellular vesicle CXCL1 from dying cells promotes triple-negative breast cancer metastasis by activating TAM/pd-l1 signaling.
Wang S; Li J; Hong S; Wang N; Xu S; Yang B; Zheng Y; Zhang J; Pan B; Hu Y; Wang Z
J Exp Clin Cancer Res; 2024 Apr; 43(1):121. PubMed ID: 38654356
[TBL] [Abstract] [Full Text] [Related]
2. Tumor-associated macrophage subtypes on cancer immunity along with prognostic analysis and SPP1-mediated interactions between tumor cells and macrophages.
Xu L; Chen Y; Liu L; Hu X; He C; Zhou Y; Ding X; Luo M; Yan J; Liu Q; Li H; Lai D; Zou Z
PLoS Genet; 2024 Apr; 20(4):e1011235. PubMed ID: 38648200
[TBL] [Abstract] [Full Text] [Related]
3. Clinical relevance of glycosylation in triple negative breast cancer: a review.
Chakraborty M; Kaur J; Gunjan ; Kathpalia M; Kaur N
Glycoconj J; 2024 Apr; 41(2):79-91. PubMed ID: 38634956
[TBL] [Abstract] [Full Text] [Related]
4. Purine metabolism in lung adenocarcinoma: A single-cell analysis revealing prognostic and immunotherapeutic insights.
Zhang P; Pei S; Zhou G; Zhang M; Zhang L; Zhang Z
J Cell Mol Med; 2024 Apr; 28(8):e18284. PubMed ID: 38597415
[TBL] [Abstract] [Full Text] [Related]
5. Suppression of AGRN enhances CD8+ T cell recruitment and inhibits breast cancer progression.
Tao J; Shen L; Zhuang M; Zhai C; Zeng H; Mao Y; Liu X
FASEB J; 2024 Apr; 38(7):e23582. PubMed ID: 38568853
[TBL] [Abstract] [Full Text] [Related]
6. Comprehensive analysis of fibroblast activation protein expression across 23 tumor indications: insights for biomarker development in cancer immunotherapies.
Dziadek S; Kraxner A; Cheng WY; Ou Yang TH; Flores M; Theiss N; Tsao TS; Andersson E; Harring SV; Bröske AE; Ceppi M; Teichgräber V; Charo J
Front Immunol; 2024; 15():1352615. PubMed ID: 38558814
[TBL] [Abstract] [Full Text] [Related]
7. [Clinicopathological characteristics and immune microenvironment of breast squamous cell carcinoma].
Liang JY; Wang YM; Wen Z; Zhang WH; Gao ZZ; Wang Z; Guo SP
Zhonghua Bing Li Xue Za Zhi; 2024 Apr; 53(4):337-343. PubMed ID: 38556816
[No Abstract] [Full Text] [Related]
8. Immunotherapeutic IL-6R and targeting the MCT-1/IL-6/CXCL7/pd-l1 circuit prevent relapse and metastasis of triple-negative breast cancer.
Haq ATA; Yang PP; Jin C; Shih JH; Chen LM; Tseng HY; Chen YA; Weng YS; Wang LH; Snyder MP; Hsu HL
Theranostics; 2024; 14(5):2167-2189. PubMed ID: 38505617
[No Abstract] [Full Text] [Related]
9. K48-linked deubiquitination of VGLL4 by USP15 enhances the efficacy of tumor immunotherapy in triple-negative breast cancer.
Wang X; Deng X; Hu J; Zheng W; Ye D; Zhou X; Fang L
Cancer Lett; 2024 Apr; 588():216764. PubMed ID: 38431034
[TBL] [Abstract] [Full Text] [Related]
10. Clinical characteristics associated with efficacy and prognosis among patients treated with PD-1/pd-l1 inhibitors for early-stage triple-negative breast cancers: A meta-analysis.
Wei Y; Wu Y; Luo Y; Ma F
Crit Rev Oncol Hematol; 2024 Apr; 196():104309. PubMed ID: 38423376
[TBL] [Abstract] [Full Text] [Related]
11. Construction of disulfidptosis-based immune response prediction model with artificial intelligence and validation of the pivotal grouping oncogene c-MET in regulating T cell exhaustion.
Li P; Wang S; Wan H; Huang Y; Yin K; Sun K; Jin H; Wang Z
Front Immunol; 2024; 15():1258475. PubMed ID: 38352883
[TBL] [Abstract] [Full Text] [Related]
12. Distinct profiles of proliferating CD8+/TCF1+ T cells and CD163+/pd-l1+ macrophages predict risk of relapse differently among treatment-naïve breast cancer subtypes.
Ntostoglou K; Theodorou SDP; Proctor T; Nikas IP; Awounvo S; Sepsa A; Georgoulias V; Ryu HS; Pateras IS; Kittas C
Cancer Immunol Immunother; 2024 Feb; 73(3):46. PubMed ID: 38349444
[TBL] [Abstract] [Full Text] [Related]
13. Progress of PD-1/pd-l1 inhibitor combination therapy in immune treatment for HER2-positive tumors.
Zhao S; Qiu Y; Yuan M; Wang Z
Eur J Clin Pharmacol; 2024 May; 80(5):625-638. PubMed ID: 38342825
[TBL] [Abstract] [Full Text] [Related]
14. The relationship between high ratios of CD4/FOXP3 and CD8/CD163 and the improved survivability of metastatic triple-negative breast cancer patients: a multicenter cohort study.
Tenggara JB; Rachman A; Prihartono J; Rachmadi L; Panigoro SS; Heriyanto DS; Sutandyo N; Nasution IR; Rahadiati FB; Steven R; Betsy R; Juanputra S; Sudoyo AW
BMC Res Notes; 2024 Feb; 17(1):44. PubMed ID: 38308298
[TBL] [Abstract] [Full Text] [Related]
15. The Association of Immune Cell Infiltration with Metastasis Location in De Novo Metastatic Triple Negative breast cancer: A Multicenter Cross-Sectional Study in Indonesia.
Tenggara JB; Rachman A; Prihartono J; Lisnawati L; Panigoro SS; Heriyanto DS; Steven R; Tandarto K; Juanputra S; Sudoyo AW
Acta Med Indones; 2023 Oct; 55(4):376-384. PubMed ID: 38213050
[TBL] [Abstract] [Full Text] [Related]
16. Immune characteristics and clinical significance of peripheral blood lymphocytes in breast cancer.
Gao H; Ouyang D; Guan X; Xu J; Chen Q; Zeng L; Pang J; Zou Q; Qian K; Yi W
BMC Cancer; 2024 Jan; 24(1):50. PubMed ID: 38195475
[TBL] [Abstract] [Full Text] [Related]
17. CRABP2 regulates infiltration of cancer-associated fibroblasts and immune response in melanoma.
Zeng S; Chen XI; Yi Q; Thakur A; Yang H; Yan Y; Liu S
Oncol Res; 2023; 32(2):261-272. PubMed ID: 38186580
[TBL] [Abstract] [Full Text] [Related]
18. Innovative Therapeutic Approaches for Patients with HER2-Positive breast cancer.
Taurelli Salimbeni B; Ferraro E; Boscolo Bielo L; Curigliano G
Cancer Treat Res; 2023; 188():237-281. PubMed ID: 38175349
[TBL] [Abstract] [Full Text] [Related]
19. Identification and verification of PTPN3 as a novel biomarker in predicting cancer prognosis, immunity, and immunotherapeutic efficacy.
Zhou Z; Lin Z; Wang M; Wang L; Ji Y; Yang J; Yang Y; Zhu G; Liu T
Eur J Med Res; 2024 Jan; 29(1):12. PubMed ID: 38173048
[TBL] [Abstract] [Full Text] [Related]
20. cancer cell-derived exosomal miR-20a-5p inhibits CD8
Li W; Han G; Li F; Bu P; Hao Y; Huang L; Bai X
Cancer Sci; 2024 Feb; 115(2):347-356. PubMed ID: 38129137
[TBL] [Abstract] [Full Text] [Related]
[Next]